Roser P, Specka M, Bonnet U, Kuhlmann T, Kuhnhold S, Steinert R
Front Psychiatry. 2024; 15:1467144.
PMID: 39737103
PMC: 11683050.
DOI: 10.3389/fpsyt.2024.1467144.
MacDonald M, Fonseca P, Johnson K, Murray E, Kember R, Kranzler H
Transl Psychiatry. 2024; 14(1):437.
PMID: 39402051
PMC: 11473550.
DOI: 10.1038/s41398-024-03143-z.
MacDonald M, Fonseca P, Johnson K, Murray E, Kember R, Kranzler H
bioRxiv. 2024; .
PMID: 38746311
PMC: 11092658.
DOI: 10.1101/2024.04.29.591734.
Rubin J, Aby E, Barman P, Tincopa M
Liver Transpl. 2024; 31(2):231-241.
PMID: 38669598
PMC: 11518881.
DOI: 10.1097/LVT.0000000000000388.
Barker B, Min J, Homayra F, Piske M, Sabeti S, Meilleur L
Drug Alcohol Depend. 2023; 250:110908.
PMID: 37544037
PMC: 10895919.
DOI: 10.1016/j.drugalcdep.2023.110908.
Gender differences in physical morbidity in opioid agonist treatment patients: population-based cohort studies from the Czech Republic and Norway.
Rolova G, Eide D, Gabrhelik R, Odsbu I, Clausen T, Skurtveit S
Subst Abuse Treat Prev Policy. 2023; 18(1):47.
PMID: 37507709
PMC: 10385939.
DOI: 10.1186/s13011-023-00557-8.
Cause-Specific Mortality among Patients in Treatment for Opioid Use Disorder in Multiple Settings: A Prospective Comparative Cohort Study.
Eide D, Skurtveit S, Clausen T, Hesse M, Mravcik V, Nechanska B
Eur Addict Res. 2023; 29(4):272-284.
PMID: 37385232
PMC: 10614278.
DOI: 10.1159/000530822.
Prevalence of alcohol consumption among clients of opioid agonist treatment (OAT) centers in Golestan province, Iran.
Noroozi A, Danesh A
Front Psychiatry. 2023; 14:1134683.
PMID: 37304429
PMC: 10248063.
DOI: 10.3389/fpsyt.2023.1134683.
Opioid agonist treatment initiation and linkage for hospitalized patients seen by a substance use disorder consultation service.
Nordeck C, Welsh C, Schwartz R, Mitchell S, OGrady K, Gryczynski J
Drug Alcohol Depend Rep. 2023; 2:100031.
PMID: 36845893
PMC: 9948812.
DOI: 10.1016/j.dadr.2022.100031.
Gabapentin increases the abuse liability of alcohol alone and in combination with oxycodone in participants with co-occurring opioid and alcohol use disorder.
Castillo F, Jones J, Luba R, Mogali S, Foltin R, Evans S
Pharmacol Biochem Behav. 2022; 221:173482.
PMID: 36244527
PMC: 10117180.
DOI: 10.1016/j.pbb.2022.173482.
The effect of concurrent access to alcohol and oxycodone on self-administration and reinstatement in rats.
Amico K, Arnold M, Dourron M, Solomon M, Schank J
Psychopharmacology (Berl). 2022; 239(10):3277-3286.
PMID: 35972517
DOI: 10.1007/s00213-022-06210-9.
Evaluation of alcohol use pattern among OST patients using alcohol biomarkers: Report from community clinics in India.
Quraishi R, Varshney M, Rao R, Ambekar A
Indian J Psychiatry. 2022; 64(3):312-315.
PMID: 35859564
PMC: 9290424.
DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_88_22.
Prevalence and correlates of intentional substance use to reduce illicit opioid use in a Canadian setting.
Klimas J, Mok W, Lake S, Socias M, DeBeck K, Hayashi K
J Subst Use. 2022; 27(3):277-282.
PMID: 35685454
PMC: 9173654.
DOI: 10.1080/14659891.2021.1941341.
Substance use disorder is associated with alcohol-associated liver disease in patients with alcohol use disorder.
Vannier A, Fomin V, Chung R, Patel S, Schaefer E, Goodman R
Gastro Hep Adv. 2022; 1(3):403-408.
PMID: 35474707
PMC: 9038113.
DOI: 10.1016/j.gastha.2022.02.004.
Substance use disorders among primary care patients screening positive for unhealthy alcohol use.
Metz V, Palzes V, Kline-Simon A, Chi F, Campbell C, Weisner C
Fam Pract. 2021; 39(2):226-233.
PMID: 34964877
PMC: 8947771.
DOI: 10.1093/fampra/cmab171.
Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.
Roache J, Pavlicova M, Campbell A, Choo T, Peavy M, Kermack A
Alcohol Clin Exp Res. 2021; 45(12):2569-2578.
PMID: 34698397
PMC: 8722377.
DOI: 10.1111/acer.14729.
Use of methamphetamine and alcohol among people with opioid use disorder and HIV in Vietnam: a qualitative study.
Edsall A, Hoffman K, Thuy D, Mai P, Hang N, Khuyen T
BMC Public Health. 2021; 21(1):1718.
PMID: 34548042
PMC: 8456677.
DOI: 10.1186/s12889-021-11783-9.
Fifty Years of Research on Prenatal Substances: Lessons Learned for the Opioid Epidemic.
Singer L, Chambers C, Coles C, Kable J
Advers Resil Sci. 2021; 1(4):223-234.
PMID: 34316723
PMC: 8312986.
DOI: 10.1007/s42844-020-00021-7.
An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders.
Mintz C, Presnall N, Xu K, Hartz S, Sahrmann J, Bierut L
Drug Alcohol Depend. 2021; 226:108886.
PMID: 34245997
PMC: 8370094.
DOI: 10.1016/j.drugalcdep.2021.108886.
Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
Xu K, Presnall N, Mintz C, Borodovsky J, Bhat N, Bierut L
JAMA Netw Open. 2021; 4(2):e210061.
PMID: 33625511
PMC: 7905500.
DOI: 10.1001/jamanetworkopen.2021.0061.